Fedratinib
Drug
Celgene Corporation
Total Payments
$402,589
Transactions
189
Doctors
46
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $355,247 | 138 | 34 |
| 2018 | $47,342 | 51 | 16 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $276,897 | 14 | 68.8% |
| Consulting Fee | $95,063 | 23 | 23.6% |
| Travel and Lodging | $24,571 | 80 | 6.1% |
| Food and Beverage | $4,629 | 69 | 1.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,428 | 3 | 0.4% |
Payments by Type
Research
$276,897
14 transactions
General
$125,691
175 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| (FEDR-CP-002 (PMC)) A Phase 1, Open-label, 2-part Study to Evaluate the Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects (BMS Study Number: CA054-P07) (FEDR-CP-002) | Celgene Corporation | $181,593 | 0 |
| A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy & Safety Study of Fedratinib in Subjects w/ DIPSS-Intermediate or High-Risk PMF, post-PV MF, or post-ET MF & Previously Treated w/ Ruxolitinib incl. Sub-study w/ concomitant Luspatercept for anemia (FEDR-MF-001) | Celgene Corporation | $80,672 | 4 |
| A Phase 1, Open-Label, Single Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Fedratinib in Subjects with Moderate and Severe Hepatic Impairment Compared with Healthy Subjects (BMS Study Number: CA054-P06) (FEDR-CP-001) | Celgene Corporation | $13,680 | 0 |
| A Phase 3 Study of [Treatment] in Patients with Mycosis Fungoides (CL-MF-13881) | Celgene Corporation | $952.00 | 2 |
Top Doctors Receiving Payments for Fedratinib
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Sioux Falls, SD | $272,613 | 8 |
| , MD, MS | Hematology & Oncology | Cleveland, OH | $8,620 | 14 |
| , M.D | Student in an Organized Health Care Education/Training Program | Houston, TX | $8,168 | 12 |
| , MD | Internal Medicine | Ann Arbor, MI | $7,888 | 6 |
| , M.D | Hematology | Tyler, TX | $6,921 | 7 |
| , MD | Hematology | Knoxville, TN | $6,846 | 5 |
| , M.D | Medical Oncology | Huntsville, AL | $6,512 | 5 |
| , M.D | Hematology | Chino, CA | $6,393 | 5 |
| , M.D | Internal Medicine | Fargo, ND | $6,236 | 6 |
| , MD | Hematology & Oncology | New York, NY | $6,008 | 10 |
| , MD | Hematology & Oncology | Dallas, TX | $5,896 | 6 |
| , M.D | Hematology & Oncology | Plantation, FL | $5,870 | 6 |
| , MD | Internal Medicine | Chicago, IL | $4,810 | 2 |
| , M.D | Specialist | Owing Mills, MD | $4,498 | 3 |
| Olatoyosi Odenike | Hematology & Oncology | Burr Ridge, IL | $3,517 | 3 |
| , M.D | Hematology | Chicago, IL | $3,517 | 3 |
| , M.D | Medical Oncology | Tinley Park, IL | $3,182 | 3 |
| , MD | Medical Oncology | Skokie, IL | $3,054 | 3 |
| Michael Thirman | Hematology & Oncology | Chicago, IL | $2,797 | 3 |
| John Quigley | Hematology & Oncology | Chicago, IL | $2,797 | 3 |
| , MD | Internal Medicine | Chicago, IL | $2,780 | 2 |
| , MD | Hematology | Evanston, IL | $2,687 | 2 |
| , MBBS | Hematology & Oncology | Fresh Meadows, NY | $2,683 | 4 |
| , M.D., PHD | Medical Oncology | Houston, TX | $1,904 | 3 |
| , MD | Hematology & Oncology | San Antonio, TX | $1,904 | 3 |
Ad
Manufacturing Companies
- Celgene Corporation $402,589
Product Information
- Type Drug
- Total Payments $402,589
- Total Doctors 46
- Transactions 189
About Fedratinib
Fedratinib is a drug associated with $402,589 in payments to 46 healthcare providers, recorded across 189 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2018 to 2019. In 2019, $355,247 was paid across 138 transactions to 34 doctors.
The most common payment nature for Fedratinib is "Unspecified" ($276,897, 68.8% of total).
Fedratinib is associated with 4 research studies, including "(FEDR-CP-002 (PMC)) A Phase 1, Open-label, 2-part Study to Evaluate the Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects (BMS Study Number: CA054-P07) (FEDR-CP-002)" ($181,593).